Clinical effects of 1,25-dihydroxyvitamin D3 in uremic patients with overt osteodystrophy.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D001847:Bone Diseases / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D002118:Calcium / Q000097:blood; D004100:Dihydroxycholecalciferols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use*; D008274:Magnesium / Q000097:blood; D008297:Male; D008875:Middle Aged; D010002:Osteitis Fibrosa Cystica / Q000188:drug therapy; D010018:Osteomalacia / Q000188:drug therapy; D010710:Phosphates / Q000097:blood; D014511:Uremia / Q000097:blood / Q000150:complications / Q000188:drug therapy*
D004100:Dihydroxycholecalciferols; D006887:Hydroxycholecalciferols; D010710:Phosphates; D000469:Alkaline Phosphatase; D008274:Magnesium; D002118:Calcium